Turinabol

Product Overview

Turanabol 20 mg by Zyvex Pharmaceuticals contains 4-Chlorodehydromethyltestosterone 20 mg per tablet and is supplied in packs of 100 tablets. The active compound is commonly known as Chlorodehydromethyltestosterone (CDMT) or Oral Turinabol.

Turinabol is an orally active synthetic anabolic-androgenic steroid (AAS) structurally related to Methandienone (Dianabol). The addition of a chlorine substitution substantially changes its pharmacological profile, particularly by preventing conventional aromatization to estrogen. It is also a 17-alpha-alkylated steroid, a modification that improves oral bioavailability but contributes to clinically important hepatic and metabolic concerns.

Turinabol was historically developed as a pharmaceutical anabolic steroid but is now best known for its association with performance enhancement and competitive-sport doping. It is not a standard contemporary treatment for testosterone deficiency or routine hormone replacement.

In non-medical performance contexts, Turinabol is generally associated with lean-tissue development, strength, nitrogen retention, and comparatively limited estrogen-related water retention. These characteristics do not establish medical safety.

The 20 mg designation describes the amount of 4-Chlorodehydromethyltestosterone contained in each tablet. It should not be interpreted as a recommended daily dose, bodybuilding cycle, or other performance-enhancement protocol.

Product Class

• Oral anabolic-androgenic steroid (AAS)
• Testosterone-derived synthetic androgen
• 4-chloro anabolic steroid
• 17-alpha-alkylated oral steroid
• Androgen receptor agonist
• Non-aromatizing anabolic steroid

Indications

Clinical Context

Chlorodehydromethyltestosterone was historically developed as an anabolic pharmaceutical and was used in selected medical contexts where anabolic support was considered desirable. Its role in contemporary evidence-based medicine is extremely limited, and it should not be assumed to have a current routine indication merely because it was previously manufactured as a pharmaceutical drug.

Turinabol is not conventional Testosterone Replacement Therapy. Although it activates androgen receptors, it cannot reproduce the complete endocrine physiology of testosterone and is not an appropriate substitute for established testosterone formulations in patients with confirmed hypogonadism.

Performance Context

Turinabol is primarily encountered today in non-medical bodybuilding and athletic-performance discussions involving:

• Lean-muscle development
• Strength progression
• Enhanced nitrogen retention
• Support of muscle protein synthesis
• Body recomposition
• Physique conditioning
• Limited direct estrogen-mediated water retention

Compared with highly aromatizable oral anabolic steroids, Turinabol is generally associated with less estrogen-mediated fluid accumulation. This can make changes in body weight appear less dramatic than with compounds such as Methandienone, but scale weight alone does not determine anabolic effectiveness.

Performance enhancement with Turinabol is non-medical, and the compound is prohibited in drug-tested competitive sport.

Mechanism of Action

4-Chlorodehydromethyltestosterone enters androgen-responsive cells and interacts with intracellular androgen receptors. The resulting receptor complex alters transcription of androgen-responsive genes and contributes to anabolic and androgenic effects.

Relevant androgen-receptor-mediated processes include:

• Muscle protein synthesis
• Nitrogen retention
• Lean-tissue metabolism
• Muscular adaptation
• Bone metabolism
• Androgenic activity in susceptible tissues

Turinabol is structurally related to Methandienone but includes a chlorine substitution at carbon 4. This modification prevents conventional aromatization and therefore differentiates its estrogenic profile from Dianabol.

Turinabol does not conventionally convert to estradiol through aromatase. Direct estrogen-mediated effects such as gynecomastia and water retention are therefore less characteristic of the compound itself than with aromatizable testosterone derivatives.

Absence of aromatization does not mean absence of endocrine effects. Exogenous Turinabol can suppress hypothalamic-pituitary-gonadal signaling, reducing LH and FSH and thereby decreasing endogenous testosterone production and spermatogenesis.

Potential Benefits

The effects commonly associated with Turinabol in performance contexts arise from its anabolic-androgenic activity. These include:

• Lean-tissue development
• Enhanced nitrogen retention
• Support of muscle protein synthesis
• Strength improvement
• Relatively limited estrogen-related water retention
• Body-recomposition effects
• Physique conditioning

Because Turinabol does not aromatize, it is not generally associated with the same degree of estrogen-mediated body-weight fluctuation as Methandienone. This does not make it medically benign.

The 17-alpha-alkylated structure introduces important hepatic considerations. Oral anabolic steroids can also produce unfavorable changes in cardiovascular risk markers, particularly reductions in HDL cholesterol and changes in other lipid parameters.

Synergy & Stacking

Turinabol is frequently discussed alongside injectable and oral anabolic agents in bodybuilding. These combinations are not medically validated treatment protocols and can increase cumulative cardiovascular, hepatic, endocrine, reproductive, and androgenic risk.

• Testosterone: Commonly discussed because Turinabol suppresses endogenous gonadal function while testosterone provides broader androgen and estrogen precursor activity.
• Testosterone Enanthate: A long-acting testosterone ester encountered in non-medical lean-mass and strength contexts.
• Primobolan: Methenolone is another non-aromatizing anabolic steroid but has different structural and metabolic characteristics.
• Masteron: Drostanolone is a DHT-derived non-aromatizing androgen commonly associated with physique-oriented applications.
• Nandrolone: A 19-nor anabolic steroid with a substantially different estrogenic, progestogenic, and androgenic profile.

Because Turinabol itself does not aromatize, an aromatase inhibitor such as Anastrozole or Exemestane does not prevent Turinabol from converting into estrogen. Whether estrogen management is medically appropriate depends primarily on other aromatizable drugs, symptoms, and laboratory findings.

Combining Turinabol with other 17-alpha-alkylated oral anabolic steroids can increase hepatic and lipid-related burden. The absence of a direct pharmacological conflict does not make such combinations clinically validated or safe.

HRT/TRT Application

Turinabol is not Testosterone Replacement Therapy (TRT). Androgen-receptor activity alone does not make an anabolic steroid a physiological testosterone substitute.

Testosterone performs important functions directly and through conversion to estradiol and DHT. These pathways contribute to sexual function, bone health, reproductive physiology, body composition, and numerous other biological processes.

Turinabol does not aromatize and cannot reproduce this complete hormonal environment. At the same time, exogenous 4-Chlorodehydromethyltestosterone can suppress LH and FSH, thereby reducing endogenous testosterone production.

Suppression can also lower intratesticular testosterone and sperm production, potentially impairing fertility.

For patients with appropriately diagnosed testosterone deficiency, established testosterone formulations such as Testosterone Enanthate, Testosterone Cypionate, or other approved testosterone products have a fundamentally different therapeutic role.

Dosing and Use

There is no medically validated contemporary bodybuilding dose or cycle for Turinabol. Performance regimens circulated in bodybuilding communities should not be interpreted as clinical dosing recommendations.

Turanabol contains 20 mg of 4-Chlorodehydromethyltestosterone per tablet. A pack of 100 tablets therefore contains a stated total of 2,000 mg of active compound. This calculation describes package composition only and does not establish an appropriate daily dose or treatment course.

The 20 mg tablet strength should not be interpreted as a universal single dose. Increasing exposure can increase hepatic, cardiovascular, endocrine, reproductive, and androgenic risk rather than simply increasing anabolic effects.

Because Turinabol is a 17-alpha-alkylated oral anabolic steroid, liver and metabolic effects are particularly relevant. Oral administration does not eliminate the need to consider systemic toxicity.

No medically validated bodybuilding loading phase, dose-escalation ladder, cycle duration, stacking dose, or post-cycle regimen can safely be inferred from the 20 mg tablet strength.

Female Use

Although Turinabol is sometimes described in performance communities as having a more favorable anabolic-to-androgenic profile than some other steroids, virilization remains a clinically important risk in women.

Potential androgenic effects include:

• Voice deepening
• Facial and body hair growth
• Acne and oily skin
• Menstrual disturbances
• Clitoral enlargement
• Changes in libido
• Androgen-related scalp hair loss

Some virilizing changes, particularly voice deepening and clitoral enlargement, can be irreversible.

The absence of aromatization does not reduce the compound's fundamental androgenic potential. Likewise, the 20 mg tablet strength should not be interpreted as a validated female performance dose.

Exposure during pregnancy presents particular concern because synthetic androgens can interfere with fetal development.

Comparative Analysis

Turinabol vs Dianabol

• Turinabol: 4-Chlorodehydromethyltestosterone, a non-aromatizing oral anabolic steroid.
• Dianabol: Methandienone, a structurally related oral anabolic steroid capable of aromatization.
• Dianabol is generally associated with greater estrogen-mediated water retention.
• Turinabol is generally associated with less fluid-related body-weight fluctuation.
• Both are 17-alpha-alkylated oral anabolic steroids with important hepatic and lipid considerations.

Turinabol vs Anavar

• Turinabol: Chlorinated testosterone-derived oral anabolic steroid.
• Anavar: Oxandrolone, a DHT-derived oral anabolic steroid.
• Neither conventionally aromatizes to estrogen.
• Both can adversely affect hepatic and lipid parameters despite their differing molecular structures.

Turinabol vs Winstrol

• Turinabol: Non-aromatizing testosterone-derived oral steroid.
• Winstrol: Stanozolol, a DHT-derived non-aromatizing anabolic steroid.
• Both are associated with strength and physique-conditioning contexts.
• Both can substantially affect lipid profiles and carry hepatic concerns when administered orally.

Turinabol vs Anadrol

• Turinabol: Commonly associated with comparatively gradual lean-mass and strength effects with limited estrogen-related fluid retention.
• Anadrol: Oxymetholone, a potent oral anabolic steroid strongly associated with rapid body-weight, strength, and fluid changes.
• Both are 17-alpha-alkylated and can impose clinically important hepatic and cardiovascular risk.

Turinabol vs Testosterone

• Turinabol: Synthetic non-aromatizing oral anabolic steroid.
• Testosterone: The principal endogenous male androgen and an established hormone-replacement medication.
• Testosterone can convert to estradiol and DHT; Turinabol does not reproduce this physiological endocrine profile.
• Turinabol is therefore not an equivalent substitute for TRT.

Conclusion

Turanabol 20 mg by Zyvex Pharmaceuticals contains 4-Chlorodehydromethyltestosterone 20 mg per tablet and is supplied in packs of 100 tablets. Commonly known as Turinabol, the compound is an orally active, non-aromatizing anabolic-androgenic steroid with historical pharmaceutical use and a prominent association with performance enhancement.

Turinabol's pharmacological profile differs from Dianabol because its 4-chloro modification prevents conventional aromatization, resulting in comparatively limited direct estrogen-mediated water retention. However, it remains a 17-alpha-alkylated oral anabolic steroid capable of causing hepatic, lipid, cardiovascular, endocrine, reproductive, and androgenic adverse effects. It is not conventional TRT, and the 20 mg tablet strength describes product content rather than a validated performance-enhancement dose.